strong>Cellular Biomedicine Group Inc., of Palo Alto, Calif., said it treated the final patient in its phase IIb trial to further evaluate the safety and efficacy of their adipose-derived mesenchymal precursor cell (haMPC)-based therapy Rejoin for knee osteoarthritis.